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In vitro susceptibility studies of 246 clinical isolates demonstrated that this antibiotic was effective against Group A beta
hemolytic streptococci, alpha hemolytic streptococci, S.
pneumoniae,
both penicillinase
producing and nonpenicillinase producing Staphylococci, Klebsiella pneumoniae, and Proteus mirabilis. Cephalothin susceptible E.
coii were also susceptible to cefaclor.
Pseudomonas
aeruginosa, Serratia sp., Enterobacter Sp., and Streptococcus faecalis were uniformly resistant to cefaclor. The
efficacy and safety of this antibiotic were studied in 27
patients with urinary tract, soft tissue, and respiratory infections. Patients with urinary tract infections became abacteriuric after 48 hours. Patients with soft tissue infections
responded well within the first week of therapy, and throat
cultures of patients with tonsillitis were negative ten days
and six weeks after treatment. The drug was well tolerated,
and no significant adverse effect was noted.

C e f a c l o r is a new, semisynthetic oral cephalosporin, structurally related to cephalexin. It is well absorbed, with no
significant side effects,^ and is more active than cephalexin
against most of the susceptible organisms.^ ' This report
deals with 1) the pharmacology, effectiveness, and tolerance
of cefaclor in treating 27 patients with infections caused by
susceptible pathogens and 2) the in vitro susceptibility of
representative clinical isolates. Clinical observations were
made at Henry Ford Hospital and compared with our earlier
results with cephalexin.''^

Materials and Methods
Laboratory studies
The susceptibility to cefaclor of 246 strains of gram-positive
and gram-negative isolates was determined by agar dilution
method with Mueller-Hinton agar (BBL), except for beta
hemolytic streptococci, to which blood was added.^'^ Antibiotics were added to the media at 50°C to avoid antibiotic
degradation. Approximately 10' organisms were added to
the media. The minimum inhibitory concentration (MIC)
was defined as the lowest concentration that inhibited
bacterial growth after 18 hours of incubation at 37°C. The
susceptibilities of the following bacteria were determined:
£. co//, Proteus mirabilis, Enterobacter sp., indole positive
Proteus, Serratia sp., staphylococci. Group A beta hemolytic
streptococci alpha streptococci,Streptococcus faecalis, and
Streptococcus pneumoniae.

t This paper received the first Annual HFH In-Training Manuscript Award.

Serum concentrations from 19 patients and volunteers were
determined by disc plate assay' using6ac///us subt///s (ATCC
6633) as the test organism.

Submitted for publication: September 15, 1978
Accepted for publication: December 13, 1978

Concentrations were determined at 1, 2, 3, 4, and 6 hours
after 250 mgand 500 mg of cefaclor had been administered
orally. The patients had received it for at least 24 hours when
the serum specimens were obtained.
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Clinical studies

Serum concentrations

The antibiotic was administered orally to 27 patients with
urinary tract infections, skin infections, bacterial pharyngitis, and pneumonia due to susceptible organisms. Eight
patients were given 750 mg per day, 10 patients were given
1000 mg per day, and 9 were given 2 gm perday for 7 to 10
days. Periodic clinical examinations were performed and
appropriate cultures were obtained before, during, and after
treatment. Safety studies included evaluations of renal,
hepatic and hematologic functions before, during and after
antibiotic administration. Patients were followed for six
weeks after treatment whenever possible.

After 250 mg of cefaclor, the mean peak serum concentration was 5.6 /i.g per ml; at the end of three hours the
concentration decreased to 1 p g per ml or less. Similar
results were obtained with the 500 mg oral dose after three
hours. Compared to cephalexin (Table I), the concentrations
were slightly less and less sustained.
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Antimicrobial activity
The in vitro activity of cefaclor and its comparison with
cephalexin and cephalothin are shown in Figures 1-9.
Cefaclor was considerably more active than cephalexin
against all gram-positive organisms tested, including Group
A beta hemolytic streptococci andS. pneumoniae. Cefaclor
was less active against both penicillinase-producing and
n o n p e n i c i l l i n a s e - p r o d u c i n g staphylococci than
cephalothin (Figures 1-5). On the other hand, all 23 strains of
entero cocci were resistant to all three antibiotics, although
for cefaclor the MIC was only 25 ju,g per ml and for
cephalexin and cephalothin, 50 /u,g/ ml.
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Susceptibility of 33 strains of Group A Beta hemolytic streptococcus.

Cefaclor was the most active ofthe three against £. coii, K.
pneumoniae, and P. mirabilis (Figures 6-8). Only 10% ofthe
strainsof Enterobacter sp. were inhibited by 25 mg per ml or
less of cefaclor, and lessthan 5% of strains were inhibited by
the same concentration of cephalexin and cephalothin
(Figure 9). All strains of indole positive proteus (13),
Pseudomonas aeruginosa (20), and Serratia sp. (12) were
uniformly resistant to all three antibiotics tested with MICs
greater than 50 p g per ml.
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TABLE 1
Serum Concentration
Of Cefaclor and Cephalexin
Hours After Dose
250 mg Orally

Cefaclor
meg/ ml

Cephalexin*
meg 'ml

1/2
1
2
3
4
5
6

4,5
5,6
1,75
1.0

5,7
10,9
4.9
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Susceptibility of 20 strains of alpha streptococcus.
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Fig. 5
Susceptibility of 18 strains of penicillinase-producing Staphylococcus
aureus.
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Fig. 4
Susceptibility of 20 stramsof nonpenicillinase-producing Sfap/iyfococcus
aureus.
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Susceptibility of 15 strains off. coii.
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One patient with Proteus mirabilis bacteriuria and one
symptomatic patient with multiple positive urine cultures
ior Staphylococcus epidermidis were treated and cured with
this antibiotic. There was no reinfection by other organisms
and only one recurrence by the same organism nine days
after treatment had been completed. Eight of 16 patients
received 250 mgevery 8 hours, andthe rest received 250 mg
every 6 hours for 7-10 days.
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Six patients were treated for soft tissue infection and abscesses. Among these, four with acute Staphylococcus
aureus infections improved on therapy, but the antibiotic
had to be stopped after three and five days in two of them
because of side effects (nausea and vomiting in one and
diarrhea in one); both were drug abusers. One patient with
mixed Staphylococcus aureus and Group A beta hemolytic
streptococcus was treated and cured with cefaclor 500 mg
every 6 hours. Clinical improvement was seen also in
another patient with polymicrobial infection due to E. coii,
A. hydrophila, and Enterobacter sp., but cultures continued
to grow Enterobacter sp.

50,0
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Fig. 7
Susceptibility of 17 strains of Klebsiella sp.

Five patients who received cefaclor for respiratory tract
infections were all cured and had negative follow-up cultures. Four of these patients had acute tonsillitis due to
Group A beta hemolytic streptococcus and one patient had
lobar pneumonia due to Streptococcus pneumoniae.

Clinical results
Cefaclor was administered to 27 patients with cultureproved urinary tract, soft tissue, and respiratory infections
caused by susceptible pathogens (Table II). Among these
patients, 16 had urinary tract infections, six had soft tissue
infections, and five had respiratory infections. Eleven patients with £. coll urinary tract infections were treated, and
10 became abacteriuric in 48 hours. In one patient, despite
clinical improvement, the antibiotic was stopped because of
reported resistance ofthe organism to cefaclor by the disc
method. Three patients with K/ebs/e/Za pneumoniae urinary
tract infection were treated, and two became abacteriuric in
48 hours. However, one patient who had lower urinary tract
obstruction secondary to prosatic hypertrophy continued to
show significant bacteriuria and required parenteral gentamicin and transurethral resection ofthe prostate for cure.

No major adverse reactions were observed with cefaclor
treatment. In two parenteral drug abusers, nausea, vomiting
and diarrhea were noted, but it was hard to distinguish those
symptoms from narcotic withdrawal symptoms. All serum
chemistries, including SCOT, SGPT, alkaline phosphatase,
bilirubin, serum creatinine and blood urea nitrogen, were
normal before, during, and after treatment, except for mild
transientelevationof SCOT in one patient. Coomb's test was
also negative in all patients. Mild eosinophilia was noted in
two patients.

TABLE II
Results of Treatment of 27 Patients with Cefaclor
Results
Poor

Diseases and No. of Cases

Organisms

Good

Fair

Urinary Tract Infection (16)

Escherichia
coii
Klebsiella
pneumoniae
Proteus
mirabilis
Staphylococcus
epidermidis
Staphylococcus
aureus
Staph, aureus -f beta h e m o l y t i c
streptococci group A
E. coii + Enterobacter
sp. -\A.
hydrophila

10
2
1
1
2

1

-

-

1

2

-

1

-

-

-

1

-

1
4

-

-

Soft Tissue Infections (6)

Respiratory Tract Infection (5)
P n e u m o n i a (1)
Tonsillitis (4)

Streptococcus
pneumoniae
Beta S t r e p t o c o c c i G r o u p A
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cephalexin and other oral or parenteral cephalosporins
against susceptible gram-negative organisms, including
Hemaphilus isolates.^'^'H'i^ Animal studies^'''^ showed that
this drug is well absorbed orally with a peak of 5.8 to 6.9 p g
per ml after a single dose of 250 mg. Our study revealed a
one-hourconcentrationof5.6/Agperml and lessthanO.1 pg
per ml after four hours. This concentration is slightly lower
and less sutained''" than cephalexin, but better results in
therapy of experimental animalscan beexplained by higher
activity against almost all susceptible organisms. Streptococcus faecalis, indole positive Proteus, Serratia sp., and
Pseudomonas aeruginosa were all uniformly resistantto this
antibiotic in our study, as was also shown in earlier reports.
Although enterobacter species were slightly more susceptible to cefaclor than cephalexin and cephalothin, only
10-30% ofthe strains have been shown to be susceptible to
cefaclor.^"®

CEFACLOR

CEPHALOTHIN

• — ——

•

CEPHALEXIN

0.4

0.8

1.6

3,2

MIC

6.4

12.8 25.6

(/xg/ml)

Fig. 8
Susceptibility of 20 strains of Proteus mirabilis.
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Although clinical trial of cefaclor is limited,^^'^^ in our study
26 of 27 infections were cured or showed significant
symptomatic improvement. Bacteriuria recurred in one
patient nine days after therapy had been completed. One
patient with urinary tract infection failed on therapy, although obstructive uropathy might account for this failure.
He also failed on cephalexin, co-trimoxazole, and amoxacillin. Cefaclor was as effective as amoxacillin in treating
lower urinary tract infections in w o m e n , I n softtissue and
respiratory tract infections, all patients but one were cured.
The one exception was a patient with polymicrobial infection secondary to drug abuse who had a continued positive
culture for enterobacter sp.

In our study, cefaclor was well absorbed orally and almost all
was excreted by the kidney It was also wel I tolerated, except
for two patients who had gastrointestinal side effects. No
significant hematologic or hepatic dysfunctions were noted.
Experimental animal studies have confirmed the safety of
this antibiotic. Large doses of cefaclor administered to
animals produced minimal changes in serum with transient
changes in hemoglobin and platelets."
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Fig. 9
Susceptibility of 13 strains of Enterobacter sp.

In conclusion, cefaclor is a wide spectrum antibiotic shown
to be well absorbed and well tolerated. It is more active in
vitro than cephalexin against all common gram-positive and
gram-negative organisms tested, and when administered
orally, it is effective against infections caused by susceptible
organisms.

Discussion
Cefaclor is a new, semisynthetic oral cephalosporin related
to cephalexin. It has wide spectrum of activity, and the
earlier reports^"® indicated greater in vitro activity against
more of the gram-positive bacteria and all ofthe susceptible
gram-negative bacteria when it was compared with other
available oral cephalosporins. Against penicillinase-producing and nonpenicillinase-producing Staphylococcus
aureus, cefaclor was more active than cephalexin but less
than cephalothin,"'^^ Against different species of strept o c o c c i , it was at least four times more active than
cephalexin."'" Cefaclor was uniformly more active than
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